these cells undergo a phenotypic modulation into a proliferative state and migrate and multiply within the intimal region of the vessel causing luminal occlusion. The entire process involves injury to the endothelium, inflammation, SMC proliferation and de novo synthesis of extracellular matrix. The synthesis of extracellular matrix component leads to vessel remodelling and these results in narrowing of the lumen.
Several growth factors including IGF-1, angiotensin II and platelet-derived growth factor lead to matrix production [5, 6] . An important goal is therefore to identify the molecular pathways and their regulators involved in SMC proliferation and using this information to develop novel therapeutic targets. Transplanting a venous segment into the arterial circulation exposes it to shear stress which leads to endothelial injury [7] which is accompanied by an accumulation of inflammatory cells and the release of growth factors and cytokines [8, 9] . The role of various growth factors including insulin-like growth factor (IGF)-1 have been reported [10, 11] . Activation of IGF-1 receptors trigger signalling pathways involving PI3K and AKT/PKB [12, 13] and are up-regulated in SMC proliferation [13] . The [14] .
IGF-1-PI3K-AKT/PKB axis mediates the balance between survival, apoptosis and proliferation. Thus, modulation of this axis could be a viable option in inhibiting SMC hyperplasia. A possible regulatory molecule could be the tumour suppressor protein, phosphatase and tensin homologue (PTEN)
PTEN is an inositol 3-phosphatase and an endogenous inhibitor of PI3K [15] . It regulates cell growth and apoptosis [16, 17] . PTEN has been shown to be a dual protein and lipid phosphatase and can hydrolyse 3Ј-phosphoinositol products to prevent downstream activation of AKT/PKB which is an effector molecule of PI3K [18] .
Adenoviral-mediated overexpression of PTEN blocked the mitogenic effects of platelet-derived growth factor (PDGF).
Overexpression of PTEN causes G1 cell cycle arrest [19] and apoptosis of SMCs by down-regulating the PI3K-AKT/PKB pathway [20] . The majority of studies relating to PTEN and SMC hyperplasia have been conducted in animal models with limited information in SV SMCs [21] . We 
Smooth muscle cell isolation and culture
SMCs from the tissue samples were isolated by a method previously reported by our laboratory for carotid plaque SMC culture [23] 
Results

Involvement of PI3K in IGF-1-mediated activation
Mitogenic stimulation with IGF-1(100 ng/ml) caused progressive increase in total PI3K expression over the course of 24 hrs (Fig. 1A) , which was significantly greater in SV SMCs than in IMA SMCs (Fig. 1B) . We also observed a progressive increase in the phosphorylated form of PI3K which persisted at 24 hrs in SV SMCs (Fig. 1A) , but not in IMA SMCs (Fig. 1B) (Fig. 3B ). (Fig. 4B ). (Fig. 6A and B) . However, PTEN overexpression had no significant effect on MDM2 and p53 expression in IMA SMCs (Fig. 6B) 
PTEN decreases cell surface IGF-1R expression
We analysed the effect of overexpression of PTEN on the molecules upstream of PI3K-AKT/PKB in SV SMCs. Following stimulation with IGF-1 (100 ng/ml), the overall levels of IGF-1R (␤-subunits) increased up to 2 hrs followed by significant decrease at 4 and 12 hrs (Fig. 4A). This was in contrast to the SV SMCs transfected with the empty vector, which showed significant increase in the IGF-1R following IGF-1 treatment and this was similar to our previous results of normal (non-transfected) SMCs stimulated with IGF-1. Inhibition of the PI3K pathway using LY294002 caused a downregulation of IGF-1R which was highly significant at 12 hrs (Fig. 4A). In IMA SMCs, IGF-1 (100 ng/ml) alone significantly induced IGF-1R expression from 2 to 4 hrs followed by decrease at 12 hrs (Fig. 4A). The effect of IGF-1 to increase IGF-1R in IMA SMCs was blocked by PTEN overexpression at 4 and 12 hrs
PTEN promotes p53 activity and regulates cellular levels of MDM2
We examined possible downstream targets of AKT/PKB and the effect of PTEN expression on the activity of MDM2, a known effector of AKT/PKB action and negatively regulates p53, which is a negative regulator of proliferation. SV and IMA SMCs stimulated with IGF-1 showed significantly increased MDM2 levels in SV SMCs at 12 and 24 hrs (Fig. 5A). In IMA SMCs, the increase was less marked and was not temporally significant. This could be attributed to the higher levels of PTEN activation demonstrated in IMA SMCs. It was surprising to see the sustained MDM2 expression in both groups of cells, since MDM2 normally has a half life of less than 1 hr. This could be due to prolonged IGF-1 stimulation. Cells after similar treatment were analysed for p53 function. Western blot assay showed a marked increase in p53 activity in the IMA SMCs as compared to the SV (Fig. 5B). We anticipated that expression of PTEN would up-regulate p53 activity and have an inverse effect on MDM2 levels. To test this, SMCs of SV and IMA overexpressing PTEN were stimulated with IGF-1 and analysed for MDM2 and p53 levels. PTEN-overexpression significantly reduced IGF-1-induced MDM2 levels and significantly increased IGF-1-induced p53 levels in SV SMCs
Discussion
SMC proliferation leading to IH is the primary pathology associated with vein graft failure [24] . PI3K and AKT/PKB are key molecules which mediate the propagation of mitogenic signals to the translation of cell cycle proteins [25, 26] . Activation of PI3K-AKT/PKB pathway has been shown to promote proliferation in a variety of cell types [27] [28] [29] [30] and there are reports that have shown increased DNA synthesis following mitogenic stimuli to be mediated via the PI3K-AKT/PKB pathway [31, 32] . AKT/PKB is directly involved in cell cycle regulation through its downstream target GSK-3␤, by preventing the phosphorylation and degradation of cyclin D1 [33] and also by negatively regulating the cyclin-dependent kinase inhibitors p21 and p27 [34, 35] . It also plays an important role in cell growth by directly phosphorylating the mammalian target of rapamycin or mTor and also inactivating tuberin (TSC2) which is an mTor inhibitor [36, 37] [45] . The PTEN tail is important for phosphorylation activity and maintaining PTEN stability [46] . Recent 
